James V. Mazzo
Share |
James V. Mazzo

Chairman & CEO, AcuFocus

James (Jim) Mazzo is the Executive Chairman and CEO of AcuFocus.  AcuFocus, a privately held ophthalmic medical device company, develops and markets breakthrough technologies for the improvement of near vision. Using the proven small aperture – or pinhole – effect, the company has developed two products: the Company’s flagship product which recently received FDA approval, the KAMRA™ corneal inlay and the innovative IC-8™ intraocular lens (IOL). The KAMRA inlay helps presbyopic patients restore their near vision while maintaining their distance vision. The IC-8 IOL provides a range of vision across various distances, from near to far, and is specifically designed for patients with cataracts.  AcuFocus also distributes the AcuTarget HD instrument, an essential tool for optimizing treatment and technology selection for a broad range of patients, including LASIK, cataract, dry eye and presbyopes.

Mr. Mazzo is also the Executive Chairman for Neurotech, a biotechnology company developing sight-saving therapies.  Neurotech’s patented core technology platform, Encapsulated Cell Therapy (ECT), is a first-in-class, novel, versatile drug delivery platform in development for the treatment of a board array of eye diseases.

Before joining AcuFocus,  Mr. Mazzo was Senior Vice President, Abbott Laboratories and President, Abbott Medical Optics, the global leader in advanced refractive technologies for eye care professionals and patients.  He assumed this position following the 2009 acquisition of Advanced Medical Optics, Inc. by Abbott [NYSE: ABT].  Headquartered in Santa Ana, California, Abbott Medical Optics offers market-leading technologies and services designed to address vision disorders at all stages of life.

Prior to the 2009 acquisition, Mr. Mazzo was Chairman and CEO of Advanced Medical Optics.  He lead the company following its 2002 spin off from Allergan [NYSE: AGN].

Under Mr. Mazzo's leadership, Advanced Medical Optics' revenue grew from  $538 million to more than $1 billion, and its market capitalization ranged from approximately $429 million to approximately $1.5 billion.  Mr. Mazzo orchestrated several strategic acquisitions by Advanced Medical Optics that were valued at more than $3 billion and transformed the company into the global leader in refractive surgery, and a major player in the cataract and eye care markets. 

Previously, Mr. Mazzo spent 22 years at Allergan, where he held a variety of senior executive-level positions. For approximately 12 years, he served Allergan outside the United States, as President of its Europe/Africa/Middle East region, Vice President and Managing Director (Italy), and Director of Marketing (Canada).

Mr. Mazzo is a Public Trustee on the Governing Board of the American Society of Cataract and Refractive Surgery (ASCRS), an international non-profit organization advancing the art and science of ophthalmic surgery.  He also holds a seat on the California Healthcare Institute (CHI), an organization for direct political involvement that works to educate legislators and positively influence healthcare laws and regulations.  Mr. Mazzo is also a member of the Medical Device Manufacturers Association (MDMA) board.  A Washington, DC-based national trade association, MDMA provides educational and advocacy assistance to innovative and entrepreneurial medical technology companies.

From 2010 to 2012, Mr. Mazzo served as Board Chairman of AdvaMed, the world's largest medical device organization. During his two-year tenure as Chairman, he led the organization's efforts to advocate for legal, regulatory and economic environments that advance global health care via patient access to life-changing medical technology.

Mr. Mazzo is a strong believer in higher education and serves on the University of California at Irvine (UCI) foundation (past Chairman).  He is a trustee for Chapman University. Additionally, he serves on the board of directors for OCTANe, Segerstrom Center for the Arts, and is a member of the International Intraocular Implant Club (IIIC).